Cybear, Mediconsult go public with merger plans
Cybear Group (part of Andrx Corporation) and Mediconsult.com have announced plans to merge in a stock-for-stock transaction. Under terms of the agreement, Mediconsult shares will be exchanged for Cybear shares at a ratio of 0.143 shares of
Cybear Group (part of Andrx Corporation) and Mediconsult.com have announced plans to merge in a stock-for-stock transaction. Under terms of the agreement, Mediconsult shares will be exchanged for Cybear shares at a ratio of 0.143 shares of Cybear stock for each share of Mediconsult. Subject to regulatory and shareholder approval, the firms expect to complete the merger in the second quarter. In the meantime, Cybear has agreed to provide interim financing to Mediconsult and to restructure its own company to reduce operating expenses. In a completely separate transaction, Cybear and Mediconsult's Physicians' Online Internet portal have entered into a strategic alliance.
In related news, Mediconsult plans to appeal Nasdaq's decision to delist Mediconsult's stock for not meeting the minimum net tangible assets requirement. Whether Mediconsult's potential delisting will affect the Cybear deal remains an open question. At press time, both Cybear and Mediconsult were trading well under $1 per share.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
